Success Metrics

Clinical Success Rate

87.5%

Based on 7 completed trials

Completion Rate

88%(7/8)

Active Trials

0(0%)

Results Posted

114%(8 trials)

Terminated

1(13%)

Phase Distribution

Ph phase_4

13%

Ph phase_2

63%

Ph phase_3

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 2Efficacy & side effects

5(62.5%)

Phase 3Large-scale testing

2(25.0%)

Phase 4Post-market surveillance

1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(7)

Terminated(1)

Detailed Status

Completed7

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

87.5%

Most Advanced

Phase 4

Trials by Phase

Phase 25 (62.5%)

Phase 32 (25.0%)

Phase 41 (12.5%)

Trials by Status

terminated113%

completed788%

Recent Activity

0 active trials

Showing 5 of 8

completedphase_2

Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

NCT00269477

completedphase_2

Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children

NCT00771849

completedphase_3

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

NCT00384397

completedphase_2

Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26

NCT00700713

completedphase_4

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age

NCT01659996

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT00269477Phase 2

Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

Completed

NCT00771849Phase 2

Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children

Completed

NCT00384397Phase 3

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

Completed

NCT00700713Phase 2

Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26

Completed

NCT01659996Phase 4

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age

Completed

NCT00772629Phase 2

Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults

Terminated

NCT00777790Phase 2

Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents

Completed

NCT01519713Phase 3

Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects

Completed

All 8 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 8